136 patents
Page 3 of 7
Utility
Methods of Treating or Preventing Autoimmune Diseases with 2,4-PYRIMIDINEDIAMINE Compounds
10 Mar 22
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases.
Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
Filed: 19 Nov 21
Utility
Compositions and Methods for Inhibition of the Jak Pathway
27 Jan 22
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
Filed: 5 Oct 21
Reissue
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
25 Jan 22
The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
Filed: 4 Mar 19
Utility
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
25 Jan 22
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases.
Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
Filed: 21 Mar 19
Utility
RIP1K Inhibitors
13 Jan 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Somasekhar BHMIDIPATI, Simon SHAW, Ihab DARWISH, Jiaxin YU, Rao KOLLURI, Vanessa TAYLOR, Esteban MASUDA, Mark IRVING
Filed: 25 Jun 21
Utility
Compounds and method for treating autoimmune diseases
11 Jan 22
Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
Filed: 26 Aug 19
Utility
Method and Composition Embodiments for Treating Acute Myeloid Leukemia
6 Jan 22
Disclosed herein are embodiments of a method and pharmaceutical composition for treating acute myeloid leukemia (AML).
Sandra Tong, Vadim Markovtsov, Ann Lowe, Anne-Marie Duliege
Filed: 31 Oct 19
Utility
Compositions and methods for inhibition of the JAK pathway
14 Dec 21
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
Filed: 26 Aug 19
Utility
Axl Inhibitors for Use In Combination Therapy for Preventing, Treating or Managing Metastatic Cancer
9 Dec 21
This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient.
Yasumichi Hitoshi, Sacha Holland, Donald G. Payan
Filed: 18 Jun 21
Utility
ACVR2A-SPECIFIC Antibody and Method of Use Thereof
9 Dec 21
The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same.
Todd M. KINSELLA, Ramesh BHATT, Kristen BALTGALVIS
Filed: 4 Aug 21
Utility
Compositions and methods for inhibition of the JAK pathway
16 Nov 21
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
Filed: 17 Oct 19
Utility
Direct AMPK activators
16 Nov 21
Simon Shaw, Xiang Xu, Sarkiz Issakani, Rajinder Singh, Yasumichi Hitoshi, Matthew Duncton, Nan Lin
Filed: 15 Aug 17
Utility
RIP1K Inhibitors
14 Oct 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Ihab Darwish, Zhushou Luo, Vanessa Taylor
Filed: 2 Apr 21
Utility
Kinase Inhibitors and Methods for Making and Using
7 Oct 21
Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors.
Vanessa Taylor, Yan Chen, Rose Yen
Filed: 8 Jun 21
Utility
Fumarate analogs and uses thereof
28 Sep 21
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders.
Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
Filed: 14 Oct 19
Utility
Method for Treatment of COVID-19-ASSOCIATED Conditions
16 Sep 21
Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient.
Esteban Masuda, Vadim Markovtsov
Filed: 18 May 21
Utility
TGF-SS Inhibitors
9 Sep 21
Marina Gelman, Pingyu Ding, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
Filed: 19 May 21
Utility
Tyrosine kinase inhibitors
7 Sep 21
Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
Filed: 19 Sep 19
Utility
2,4-PYRIMIDINEDIAMINE Compounds and Their Uses
2 Sep 21
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipsti, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 3 May 21
Utility
ACVR2A-specific antibody and method of treatment of muscle atrophy
31 Aug 21
The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same.
Todd M. Kinsella, Ramesh Bhatt, Kristen Baltgalvis
Filed: 27 Mar 18